Already have an account?


Login with an existing Projects In Knowledge account
New to Projects In Knowledge?


Register today to customize your experience.
Log In
Don't have an account yet? Click here to register



Register for Free
Already have an account? Click here to log in



Enter your current email address.  Your email address will be your user name, and where you will receive confirmation of this registration.



Forgot Password

Please Enter your email address.




  Terms & Conditions                                                                                                                                     

Privacy Policy

Projects In Knowledge is committed to protecting the privacy and confidentiality of visitors to our Web site. While Projects In Knowledge does not require that you provide us with personally identifiable information in order to visit our Web site, please note that in order to participate in the continuing medical education activities that we provide, it will be necessary for you to register with us and provide this information.

About this Privacy Policy
www.projectsinknowledge.com is our Web site for physicians and allied health care professionals, although it is open to non-professionals as well. The purpose of projectsinknowledge.com is to provide continuing medical education for healthcare professionals, and is intended for use only by a licensed healthcare professional.

Projects In Knowledge is the name we use to refer to our entire company, even though our formal corporate name is Projects In Knowledge, Inc. When we refer to ourselves as "we" or "Projects In Knowledge," we mean our company, Projects In Knowledge, Inc., including any subsidiary that we control (for example, a subsidiary that we own). We may share information among our subsidiaries that we own or control, but it is always protected under the terms of this privacy policy.

This privacy policy applies only to the Projects In Knowledge Web site. You should read the privacy policy at each Web site that you visit after you leave our site. We are not responsible for how other Web sites treat your privacy, once you leave the Projects In Knowledge site.

Privacy Policy Changes
If we change our privacy policy, we will post those changes on this page. Users should check this policy to keep abreast of any changes.

Information We Collect
In this section of our privacy policy, we discuss the different types of information we may collect about you, and the ways in which we collect them.

Information We Collect from Unregistered Visitors
Visitors to our Web site can access the Web site's home page and browse the site without disclosing any personally identifiable information. We do track information provided to us by your browser, including the Web site you came from (known as the "referring URL"), the type of browser you use, the time and date of access, and other information that does not personally identify you.

Information We Collect When You Register
Customers registering on our Web site for continuing medical education activities we provide are asked to provide us with identifying information, such as name, contact information, and other identifying information. On our registration screens, we clearly label which information is required for registration, and which information is optional and may be given at your discretion.

On our registration screens you will also find a “Burning Question” field. Submission of a “Burning Question” is completely voluntary. By submitting a “Burning Question,” you grant Projects In Knowledge the right to share it with faculty to consider as they prepare their continuing medical education presentations.

Listserves
When you are using a listserve—or member-only discussion board— on our Web site, you are posting a message and your user name, which is available for all registered members to see. You should not post any information to our listserves you want to keep private. It is a condition of our Web site that when participating in a listserve, you do not:

  • Restrict or inhibit any other user from using the listserve
  • Post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including, without limitation, any transmission constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or foreign law
  • Post or transmit any information, software or other material which violates or infringes upon the rights of others, including material which constitutes an invasion of privacy or infringement of publicity rights or which is protected by copyright, trademark or other proprietary right, or derivative works thereof, without first obtaining permission from the owner or right holder
  • Post or transmit any information, software or other material which contains a virus or other harmful component
  • Post, or transmit, or in any way exploit any information, software or other material for commercial purposes which contains advertising, promotions or marketing

By sending a message through the listserve, you grant Projects In Knowledge the non-exclusive right and license to display, copy, publish, distribute, transmit, print, and use such information. Projects In Knowledge reserves the right to terminate your access to, and use of, the listserve if you do not abide by these conditions.

Use of Cookies
Cookies are a technology used by the Projects In Knowledge Web site to identify a user as the user moves through the Web site. Your browser allows us to place some information on your computer's hard drive that identifies the computer you are using. We use cookies to track your usage throughout our Web site.

Your Web browser can be set to allow you to control whether you will accept cookies, reject cookies, or to notify you each time a cookie is sent to you. If your browser is set to reject cookies, Web sites that are cookie-enabled will not recognize you when you return to the Web site, and some Web site functionality may be lost. The Help section of your browser will tell you how to prevent your browser from accepting cookies.

Although cookies do not normally contain personally identifiable information, if you are a registered user we may associate your registration information with cookies our Web site places on your computer's hard drive. Associating a cookie with your registration data allows us to offer increased personalization and functionality. For example, you can elect to have our Web site "remember" you and bypass the registration process each time you register for one of our educational activities. Without cookies, this functionality would not be possible. Projects In Knowledge does not currently employ cookies for this use, but is considering it to make our registration processes more efficient for you.

Children's Privacy
Projects In Knowledge's Web site is designed and intended for use by adults, and is not intended for, nor designed to be used by children under the age of 18, or any other unlicensed, untrained individuals. We do not collect personally identifiable information from any person we know is a child under the age of 18.

Uses We Make of Information
In this section of our privacy policy, we identify the ways we may use information about you that we have collected.

Aggregate Data
We create aggregate data about visitors to our Web site for activity development and improvement. We also use it for market analysis. We may provide information from our Web site in aggregate form, with identifying information removed, to third parties. For example, we may tell a third party what percentage of our registered users reside in a particular geographical area. When aggregated information is provided, we pool it from many individual records and strip it of any data that could be used to identify an individual before it is used. Any third party that receives aggregated data must agree not to attempt to re-identify the people it belongs to. Projects In Knowledge does not sell any user data to any third party for commercial purposes.

Third Parties
In addition to aggregate information (discussed previously), we may share some kinds of information with third parties as described below.

  • Business Transfers: If we transfer a business unit (such as a subsidiary) or an asset (such as a Web site) to another company, we will require them to honor the applicable terms of this privacy policy.

Protection of Information
In this section of our privacy policy, we discuss the security measures we take to protect information that we have collected about you.

General Policies
We have implemented technology and security policies, rules and other measures to protect the personal data that we have under our control from unauthorized access, improper use, alteration, unlawful or accidental destruction, and accidental loss. We also protect your information by requiring that all our employees and others who have access to or are associated with the processing of your data respect your confidentiality. In addition, we have appropriate security measures in place in our physical facilities to protect against the loss or misuse of information at our site that we have collected from you.

Projects In Knowledge Employees
Projects In Knowledge employees are required to keep customer information private, as a condition of their employment with the company. Only selected, authorized Projects In Knowledge employees are permitted to access your registration information.
Employees are required to sign a confidentiality agreement. All employees and contractors must abide by our privacy policy, and those who violate that policy are subject to disciplinary action, up to and including termination of their employment and legal action.

Privacy Questions or Concerns about Our Web Site
For privacy questions or concerns about the Projects In Knowledge Web site, please contact privacy@projectsinknowledge.com.

Revision date: This policy was last updated on September 30, 2003.



New and Noteworthy


  • Ovarian Cancer — SGO: Veliparib Add-on to Chemo Benefits Ovarian Ca Patients Independent of HRD Status – BreakingMED
  • PARP-inhibitors are gaining usage in the treatment of ovarian cancer. This report, which was released online following the cancellation of the 2020 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer looks at which biomarkers are most predictive of response to PARP-inhibitor therapy.
    V. Abramson, MD
  • Ovarian Cancer — SGO: Niraparib Does Not Compromise QoL in Maintenance Setting for Advanced Ovarian Cancer – BreakingMED
  • The PARP-inhibitor niraparib has been proven to significantly increase progression-free survival in patients with ovarian cancer. This report, which was released online following the cancellation of the 2020 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer, assessed nariparib’s effect on ... more >>
    V. Abramson, MD
  • Asthma — Asthma Putting It in Practice: Insights From ACAAI – Webcast
  • ACAAI 2019 showcased the latest asthma research findings as well as insights from clinical practice. In this exclusive video Weily Soong, MD, of the Alabama Allergy & Asthma Center, reviews those findings and explains how they can be applied to daily clinical practice.
    W. Soong, MD
  • Heart Failure — ACC: PARAGON-HF Analysis Confirms Predictive Role of NT-proBNP – BreakingMED
  • Is there are case to be made for using ARNI to treat preserved ejection fraction heart failure? Results of the PARAGON-HF trial failed to provide evidence to support that case, yet the findings did point to an undeniable benefit in some groups, and in this report from ACC.2020/WCC Virtual, researchers suggest ... more >>
    V. Abramson, MD
  • Heart Failure — ACC: At Last, an Abundance of Treatments for HFrEF – BreakingMED
  • Treatment of reduced ejection fraction heart failure has rapidly evolved in recent years with the addition of ARNI and SGLT2 inhibitors, and now a novel agent, vericiguat, may be added. This report reviews how this emerging polypharmacy may be tailored to the individual patient.
    K. Rodowicz, DO
  • Multiple Sclerosis — Managing a RRMS Patient with Ongoing Disease Activity Despite Adherence to Therapy – Webcast
  • This case illustrates the treatment of a patient with relapsing remitting multiple sclerosis (RRMS) with a preference for oral treatment. However, despite good adherence, the patient continues to have disease activity. The case highlights considerations when switching treatments, and methods to individualize ... more >>
    F. Lublin, MD
  • Heart Failure — ACC: On Second Analysis, DAPA-HF Benefit Is Durable – BreakingMED
  • Findings from the DAPA-HF trial were a showstopper at the European Society of Cardiology meeting in Paris last year, but that presentation was a time-to-first-event analysis, which may overestimate the treatment benefit. However, this secondary analysis presented at ACC/WCC 2020 shows that this is not the ... more >>
    V. Abramson, MD
  • Heart Failure — ACC: Targeting NO Bioavailability, VICTORIA is Victorious – BreakingMED
  • After years of disappointing results in heart failure trials, clinicians are now being presented with the possibility that another agent—a novel oral soluble guanylate cyclase stimulator—may provide benefit for patients with reduced ejection fraction heart failure, according to the VICTORIA investigators who ... more >>
    V. Abramson, MD
  • Heart Failure — Management of a Patient With HFrEF Who Develops a Cough – @Point of Care Chapter
  • Patients with heart failure with reduced ejection fraction (HFrEF) should be managed using guideline-directed medical therapy (GDMT), which includes agents that block the renin-angiotensin system, such as ACE inhibitors, ARBs, or ARNIs. This case illustrates the real-life clinical scenario of a patient who ... more >>
    J. Butler, MD, MPH, MBA
  • Psoriatic Arthritis — Case Study: Differentiating Psoriatic Arthritis From Rheumatoid Arthritis – @Point of Care Chapter
  • Patients with psoriasis can develop psoriatic arthritis (PsA). PsA has a heterogeneous clinical presentation, and it is important to differentiate it from other musculoskeletal conditions in order to ensure appropriate treatment. Join Sergio Schwartzman, MD, as he discusses a patient with a family history of ... more >>
    S. Schwartzman, MD
  • State of the Science: Multiple Sclerosis Innovations
  • State of the Science: Multiple Sclerosis Innovations provides comprehensive and up-to-date best practices in multiple sclerosis management. This includes innovative webcasts derived from major scientific conferences synthesized for the practicing clinician, interactive practice-based cases, and articles from ... more >>
    A. Cross, MD
    P. Peck, Editor-in-Chief
  • Master Class: Chronic Lymphocytic Leukemia
  • Master Class: Chronic Lymphocytic Leukemia (CLL) is designed to highlight relevant, practical advances in the treatment of CLL using a modular structure to provide an in-depth review of best practices with multiple complementary activities, including video webcasts with expert clinical specialists, case ... more >>
    B. Cheson, MD, FACP, FAAAS
  • The Art & Science of Heart Failure Management
  • The Art & Science of Heart Failure Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in heart failure ... more >>
    J. Udelson, MD
  • Pulmonology Mastery in COPD
  • Pulmonology Mastery in COPD is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in COPD. The curriculum includes ... more >>
    B. Make, MD
  • Mastery of Medicine in Diabetes Management
  • Mastery of Medicine in Diabetes Management is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in diabetes ... more >>
    V. Fonseca, MD, FRCP
  • Clinical Context: Stroke Prevention in Atrial Fibrilation
  • Clinical Context: Stroke Prevention in
    Atrial Fibrillation
    is designed to provide up-to-date information on patient identification, risk factors, and current and emerging treatments and best practices in the management of atrial fibrillation.

    The curriculum includes:
    • 6 case studies
    • MedPage Today meeting
    ...
    more >>
    C. Yancy, MD, MSc
  • Hematology Mastery in Multiple Myeloma
  • Hematology Mastery in Multiple Myeloma is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple myeloma. ... more >>
    N. Raje, MD
  • Rheumatology Mastery in Rheumatoid Arthritis
  • Rheumatology Mastery in Rheumatoid Arthritis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in rheumatoid ... more >>
    M. Husni, MD, MPH
  • Neurology Mastery in Multiple Sclerosis
  • Neurology Mastery in Multiple Sclerosis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in multiple sclerosis. ... more >>
    J. Bowen, MD
  • Rheumatology Mastery In Ankylosing Spondylitis
  • Rheumatology Mastery in Ankylosing Spondylitis is designed to provide new information based on breaking medical news, new data presented at medical meetings, and case studies on current and emerging management strategies on the most up-to-date evidence-based medicine and clinical trial results in ankylosing ... more >>
    J. Reveille, MD
  • Ovarian Cancer @Point of Care
  • Ovarian cancer is often advanced at the time of diagnosis. Although most patients respond to initial treatment, relapse is common. With the approval of new therapies and better biomarkers of response, health outcomes for women with advanced ovarian cancer have improved significantly.
    B. Monk, MD, FACS, FACOG
  • Pulmonary Arterial Hypertension @Point of Care
  • Pulmonary arterial hypertension (PAH) is a rare disorder associated with significant morbidity and mortality. Three PAH treatment pathways or targets have been identified—the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway. In 1995 the FDA approved the first treatment specifically ... more >>
    R. Channick, MD
  • Bipolar Disorder @Point of Care
  • Bipolar disorder is a common mental illness that can have a devastating impact on people’s lives without effective treatment. Important developments in the understanding of bipolar disorder and its treatment have occurred in the past few years, with several new medications and formulations developed and ... more >>
    M. Thase, MD
  • Classical Hodgkin Lymphoma @Point of Care
  • Classical Hodgkin lymphoma (CHL) has a high cure rate with available therapies - nearly 90% - yet advances continue to be made to individualize therapy, minimize the risk of late toxicity, and expand therapeutic options. Current first-line treatment strategies for patients with early- and advanced-stage CHL ... more >>
    C. Moskowitz, MD
  • Nontuberculous Mycobacterial Lung Disease @Point of Care
  • Nontuberculous mycobacterial (NTM) lung disease, a condition of progressive lung damage caused by mycobacterial species other than those that cause tuberculosis or leprosy, is occurring with increasing frequency in the United States. Characterized by difficulties in diagnosis, non-FDA-approved treatment ... more >>
    N. Schluger, MD
  • Heart Failure @Point of Care
  • Heart failure is a significant health burden and, with increasing comorbidities and the aging of the population, this burden is likely to worsen especially in certain populations. Guideline-directed medical therapies have been shown to reduce morbidity and mortality in patients with heart failure, but are ... more >>
    G. Fonarow, MD
  • Alzheimer's Disease @Point of Care
  • This @Point of Care is a comprehensive, continually updated resource developed to enhance compliance to established clinical guidelines to improve screening and timely diagnosis of Alzheimer’s disease (AD) and to support current best practices of managing the symptoms of AD.
    R. Turner, MD, PhD
  • Atopic Dermatitis @Point of Care
  • Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, and recent advances in the understanding of the immune and inflammatory processes involved in AD pathogenesis have led to the development and approval of novel therapies for the treatment of this disease. With ... more >>
    L. Eichenfield, M.D.
  • Hepatocellular Carcinoma @Point of Care
  • This @Point of Care provides a comprehensive, continually updated resource to the clinical care team with relevant and current evidence-based medicine and clinical trial data for approved and emerging therapies to help tailor treatment based on patient characteristics in order to improve the management of ... more >>
    G. Abou-Alfa, MD, MBA
  • Ovarian Cancer — SGO: Veliparib Add-on to Chemo Benefits Ovarian Ca Patients Independent of HRD Status – BreakingMED
  • PARP-inhibitors are gaining usage in the treatment of ovarian cancer. This report, which was released online following the cancellation of the 2020 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer looks at which biomarkers are most predictive of response to PARP-inhibitor therapy.
    V. Abramson, MD
  • Ovarian Cancer — SGO: Niraparib Does Not Compromise QoL in Maintenance Setting for Advanced Ovarian Cancer – BreakingMED
  • The PARP-inhibitor niraparib has been proven to significantly increase progression-free survival in patients with ovarian cancer. This report, which was released online following the cancellation of the 2020 Society for Gynecologic Oncology Annual Meeting on Women’s Cancer, assessed nariparib’s effect on ... more >>
    V. Abramson, MD
  • Heart Failure — ACC: At Last, an Abundance of Treatments for HFrEF – BreakingMED
  • Treatment of reduced ejection fraction heart failure has rapidly evolved in recent years with the addition of ARNI and SGLT2 inhibitors, and now a novel agent, vericiguat, may be added. This report reviews how this emerging polypharmacy may be tailored to the individual patient.
    K. Rodowicz, DO
  • Heart Failure — ACC: PARAGON-HF Analysis Confirms Predictive Role of NT-proBNP – BreakingMED
  • Is there are case to be made for using ARNI to treat preserved ejection fraction heart failure? Results of the PARAGON-HF trial failed to provide evidence to support that case, yet the findings did point to an undeniable benefit in some groups, and in this report from ACC.2020/WCC Virtual, researchers suggest ... more >>
    V. Abramson, MD
  • Heart Failure — ACC: On Second Analysis, DAPA-HF Benefit Is Durable – BreakingMED
  • Findings from the DAPA-HF trial were a showstopper at the European Society of Cardiology meeting in Paris last year, but that presentation was a time-to-first-event analysis, which may overestimate the treatment benefit. However, this secondary analysis presented at ACC/WCC 2020 shows that this is not the ... more >>
    V. Abramson, MD
  • Heart Failure — ACC: Targeting NO Bioavailability, VICTORIA is Victorious – BreakingMED
  • After years of disappointing results in heart failure trials, clinicians are now being presented with the possibility that another agent—a novel oral soluble guanylate cyclase stimulator—may provide benefit for patients with reduced ejection fraction heart failure, according to the VICTORIA investigators who ... more >>
    V. Abramson, MD
  • Tumor Immunology — Guidelines on Adverse Events + Real World Scenarios—Lung irAEs – Webcast
  • Pulmonary immune-related adverse events have a relatively low incidence in patients who are on checkpoint inhibitor therapy but carry a high risk of mortality if not identified early. These and other immune-related adverse events emerge from the unique mechanism of action of checkpoint inhibitors and must be ... more >>
    V. Velcheti, MD
  • Cystic Fibrosis — Lumacaftor/Ivacaftor Combo Improves BMI/QoL in Cystic Fibrosis Patients with Normal Lung Function – BreakingMED
  • Lumacaftor/ivacaftor continues to show benefit for the treatment of cystic fibrosis. This report looks at nutritional status, sweat chloride levels, and exacerbation rates among cystic fibrosis patients with normal lung function at baseline.
    A. Brixey, MD
  • COPD — Antibiotics, Steroids Reduce Tx Failure for Patients with COPD Exacerbations – BreakingMED
  • Managing COPD exacerbations is clinically challenging, but a systematic review and meta-analysis suggests that use of antibiotics and corticosteroids appears to reduce treatment failure. Nonetheless, researchers were unable to identify an optimum antibiotic/corticosteroid combination.
    A. Brixey, MD
  • Tumor Immunology — Guidelines on Adverse Events + Real World Scenarios—Endocrine irAEs – Webcast
  • Endocrinopathies are relatively common and often irreversible immune-related adverse events associated with immune checkpoint inhibitor therapy. These and other immune-related adverse events emerge from the unique mechanism of action of checkpoint inhibitors and must be addressed differently than adverse ... more >>
    V. Velcheti, MD
  • Asthma — Case Study: Investigational Single-Inhaler Triple Therapy for Uncontrolled Asthma – Case Study
  • Asthma is a heterogeneous disease in which treatment with inhaled corticosteroids (ICS), with or without a long-acting beta-2 agonist (LABA) bronchodilator, is highly effective. Yet, up to 40% of patients remain uncontrolled after stepwise increases in therapy. Even with the availability of add-on biologics ... more >>
    W. Soong, MD
  • Asthma — Case Study: Management of a Patient With Severe Eosinophilic Asthma – Case Study
  • Severe asthma may remain uncontrolled with inhaled corticosteroids and a long-acting bronchodilator, despite optimal treatment and good adherence, and management often requires use of periodic or maintenance oral corticosteroids. Type 2 inflammation, characterized by the presence of interleukin (IL)-4, IL-5, ... more >>
    J. Corren, MD
  • Metastatic Melanoma — Checkpoint Inhibitor Therapy for Newly Diagnosed Stage IV Melanoma – Case Study
  • Immunotherapy with immune checkpoint inhibitors is the current standard of care for the first-line treatment of metastatic melanoma. Combination immunotherapy with an anti-CTLA-4 agent and an anti-PD-1 agent can yield improved outcomes, but comes with the risk of increased grade 3/4 treatment-related adverse ... more >>
    A. Pavlick, DO, MBA
  • Heart Failure — Optimizing Treatment for a Patient With Hypertension and HFrEF – Case Study
  • Patients with heart failure with reduced ejection fraction should be managed using recent clinical trial outcomes and guideline-directed medical therapy (GDMT), which include agents that block the renin-angiotensin-aldosterone system. This case illustrates the real-life clinical scenario of a patient who ... more >>
    K. Ferdinand, MD
  • Multiple Sclerosis — Managing RRMS Patient who Converted to SPMS – Case Study
  • This case illustrates the management of a patient who progresses from clinically isolated syndrome to relapsing multiple sclerosis (MS) and, eventually, secondary progressive MS (SPMS). It highlights treatment considerations for each stage of disease, with attention to the options that have been approved in ... more >>
    P. Coyle, MD
  • Multiple Sclerosis — Managing Highly Active Disease in an RRMS Patient with Worsening on Initial Treatment – Case Study
  • This case illustrates the treatment strategy employed for a RRMS patient who has high MS disease activity despite adherence to first-line injectable disease-modifying therapy. It highlights switching strategies that can be considered for such patients, and reviews safety and efficacy data for approved high- ... more >>
    P. Repovic, MD
  • Asthma — Case Study: Biologic Therapy for Allergic Asthma – Case Study
  • For patients with severe allergic asthma who are not adequately controlled with inhaler therapy, it may be necessary to consider the addition of biologic therapy. Choosing among the available biologic therapies involves taking into account the patient's asthma endotype based on biomarkers such as eosinophil ... more >>
    E. DiMango, MD
  • Multiple Sclerosis — RRMS Patient with Active On-Treatment Disease Considering a Switch to a Selective Oral S1P Inhibitor – Case Study
  • In this case, the diagnosis and initial treatment of a patient with relapsing multiple sclerosis (MS) is reviewed. This illustrates the considerations that occur when a patient has a clinical relapse while on disease-modifying therapy and highlights available and emerging oral therapies for the treatment of ... more >>
    C. Azevedo, MD, MPH
  • Multiple Sclerosis — Case Study: Misdiagnosis in MS – Case Study
  • The 2017 revisions to the McDonald criteria have refined the diagnosis of multiple sclerosis (MS). However, these criteria must only be applied to patients with symptoms typical of demyelination. In addition, there must be "no better explanation." This case follows the skillful navigation of diagnosis in a 56 ... more >>
    A. Solomon, MD
  • Multiple Sclerosis — Risk-Averse RRMS Patient With a Preference for an Oral DMT – Case Study
  • This case demonstrates the real-life clinical scenario of a patient with relapsing remitting multiple sclerosis (RRMS) who has a clinical relapse on his first disease-modifying therapy. It illustrates considerations when switching medications, including patient preference for therapeutic delivery, and ... more >>
    J. Bowen, MD